Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
— GOLDEN-5Official title:
A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Verified date | February 2018 |
Source | Sunovion Respiratory Development Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® [tiotropium] given as 18 mcg once a day).
Status | Completed |
Enrollment | 1087 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female patients age = 40 years, inclusive. 2. A clinical diagnosis of COPD according to the GOLD 2014 guidelines. 3. Current smokers or ex-smokers with at least 10 pack-year smoking history (eg, at least 1 pack/day for 10 years, or equivalent). 4. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1 < 80% of predicted normal and > 0.7 L during Screening (Visit 1). 5. Post-bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio < 0.70 during Screening (Visit 1). 6. Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines (2005). 7. Subject, if female = 65 years of age and of child bearing potential, must have a negative serum pregnancy test at Visit 1. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study and must use an acceptable method of birth control: a) an oral contraceptive, an intrauterine device (IUD), implantable contraceptive, transdermal or injectable contraceptive for at least 1 month prior to entering the study with continued use throughout the study and for thirty days following participation; b) barrier method of contraception, e.g., condom and /or diaphragm with spermicide while participating in the study; and/or c) abstinence.. 8. Willing and able to provide written informed consent. 9. Willing and able to attend all study visits and adhere to all study assessments and procedures. Exclusion Criteria: 1. Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject. 2. Concomitant clinically significant respiratory disease other than COPD (eg, asthma, tuberculosis, bronchiectasis or other non-specific pulmonary disease). 3. Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to Screening (Visit 1). 4. Use of daily oxygen therapy > 12 hours per day. 5. Respiratory tract infection within 6 weeks prior to Screening (Visit 1). 6. Use of systemic steroids within 3 months prior to Screening (Visit 1). 7. History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin. 8. Prolonged QTc (> 450 msec for males and > 470 msec for females) during Screening (Visit 1), or history of long QT syndrome. 9. History of or clinically significant ongoing bladder outflow obstruction or history of catheterization for relief of bladder outflow obstruction within the previous 6 months. 10. History of narrow angle glaucoma. 11. History of hypersensitivity or intolerance to aerosol medications. 12. Recent documented history (within the previous 3 months) of substance abuse. 13. Significant psychiatric disease that would likely result in the subject not being able to complete the study, in the opinion of the Investigator. 14. Participation in another investigational drug study where drug was received within 30 days prior to Screening (Visit 1) or current participation in another investigational drug trial, including a SUN-101 study. 15. Previously received SUN-101 (active treatment; formerly known as EP-101). 16. Contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, beta2 agonists, or sympathomimetic amines. |
Country | Name | City | State |
---|---|---|---|
Czechia | Medicentrum Beroun s.r o. | Beroun | |
Czechia | MediTrial, s.r.o Internf a pneumoloqicka ambulance | Jindrichuv Hradec | |
Czechia | Nemocnice Kyjov, p.o. | Kyjov | |
Czechia | Plicni ambulance | Neratovice | |
Czechia | MephaCentrum, a s Plicni oddeleni | Ostrava - Poruba | |
Czechia | MephaCentrum, a.s. | Ostrava-Poruba | |
Czechia | PNEUMa-HOST s LO. | Praha | |
Czechia | PLiCNI AMBULANCE ROKYCANY, s.r o. | Rokycany | |
Czechia | Hrudnf ambulance s.r.o. | Zatec | |
Hungary | Dr. Kenessey Albert Korhaz-Rendetointezet, TOd6gy6gyaszati | Balassagyarmat | |
Hungary | Csornai Margit Korhaz, TOd6gy6gyaszat | Csorna | |
Hungary | Kenezy Gyula Korhaz es Rendelomtezet, Klinikai Farmakologiai | Debrecen | |
Hungary | Veszprern Megyei Tudbgyogyintezet | Farkasgyepu | |
Hungary | Somogy Megyei Kaposi M6r Oktat6 Korhaz, Tudoqondozo | Kaposvar | |
Hungary | Lumniczer Sandor Korhaz as Rendelointezet, Tudoqondozo | Kapuvar | |
Hungary | Selye Janos Korhaz es Rendelointezet, Tud6gy6gyaszati Szakrendeles | Komárom | |
Hungary | Szakorvosi Rendelointezet Monor, Tudoqondozo | Monor | |
Hungary | Revamed Eqeszsequqyi Szolqaltato Kft. | Nyiregyhaza | |
Hungary | Si6fok Kornaz-Rendelointezet, Tudoqondozo | Siofok | |
Hungary | Farmakontroll Egeszsegugyi Szolqaltato Bt | Szazhalombatta | |
Hungary | Csonqrad Megyei Mellkasi Beteqseqek Szakkorhaza, Tudoqondozo lntezet | Szeged | |
Russian Federation | Territorial SBI of Healthcare <Territorial Clinical Hospital> | Barnaul | |
Russian Federation | FSBI Far Eastern Research Centre ofPhysiology and Pathology of Breathing of Siberian branch of RAMS | Blagoveshchensk | |
Russian Federation | SBI of Healthcare Regional Clinical Hospital #4 City consultative department for pulmonological patientsr | Chelyabinsk | |
Russian Federation | Municipal Autonomous Institution (City ClinicalHospital #14) | Ekaterinburg | |
Russian Federation | FSSI Scientific Research Institute of Complex Cardiovascular Pathology | Kemerovo | |
Russian Federation | Municipal Budget Institution of Healthcare (City Clinical Hospital #3 n.a. M.A. Podgorbunsky) | Kemerovo | |
Russian Federation | FSBI | Moscow | |
Russian Federation | Non-State Private Institution of Healthcare <Scientific Clinical Center> | Moscow | |
Russian Federation | SBI of Healthcare of Nizhny-Novgorod region | Nizhny-Novgorod | |
Russian Federation | SB1 of Healthcare of Novosibirsk region <Novosibirsk State Regional Clinical Hospital>l | Novosibirsk | |
Russian Federation | SBI of Healthcare of Novosibirsk region <Novosibirsk State Regional Clinical Hospital> | Novosibirsk | |
Russian Federation | SBEI of HPE <North-West State Medical University n.a. LL Mechnikov> | Saint-Petersburg | |
Russian Federation | Alliance Biomedical, Russian Group LLC | St. Petersburg | |
Russian Federation | SBr of Helathcareof Yaraslavl region Clinical Hospital of Emervency care n.a.N.V. Solovyev | Yaroslavl | |
United States | SEC Lung LLC | Andalusia | Alabama |
United States | Achieve Clinical Research LLC | Birmingham | Alabama |
United States | Tampa Bay Clinical Research Center | Brandon | Florida |
United States | Cadillac Clinical Research LLC | Cadillac | Michigan |
United States | Clinical Research Advantage, Inc.lEast Valley Family Physicians, PLC | Chandler | Arizona |
United States | Lowcountry Lung and Critical Care, PA | Charleston | South Carolina |
United States | American Health Research, Inc. | Charlotte | North Carolina |
United States | IVA Researcb | Cincinnati | Ohio |
United States | Clinical Research of West Florida | Clearwater | Florida |
United States | H.C. Research LLC | Coeur d'Alene | Idaho |
United States | Howard County Center for Lung and Sleep Medicine, LLC | Columbia | Maryland |
United States | Remington Davis Inc | Columbus | Ohio |
United States | Corsicana Medical Research, PLLC | Corsicana | Texas |
United States | Avail Clinical Research, llC | DeLand | Florida |
United States | Easley Clinical Research | Easley | South Carolina |
United States | Palmetto Medical Research Associates | Easley | South Carolina |
United States | Minnesota Lung Center | Edina | Minnesota |
United States | Evanston Premier Healthcare Research LLC | Evanston | Illinois |
United States | Lillestol Research, LLC | Fargo | North Dakota |
United States | Abraham Research, PLLC | Fort Mitchell | Kentucky |
United States | Allianz Research Institute, Inc. | Fountain Valley | California |
United States | Research Center of Fresno, Inc. | Fresno | California |
United States | California Research Medical Group, lnc. | Fullerton | California |
United States | Gaffney Pharmaceutical Research | Gaffney | South Carolina |
United States | Spectrum Medical Research, LLC | Gaffney | South Carolina |
United States | Greenville Pharmaceutical Research, Inc. | Greenville | South Carolina |
United States | Upstate Pharmaceutical Research, Inc. | Greenville | South Carolina |
United States | DeGarmo Institute of Medical Research | Greer | South Carolina |
United States | Kentucky Lung Clinics, PSC | Hazard | Kentucky |
United States | The Community Research of South Florida | Hialeah | Florida |
United States | Pioneer Research Solutions, Inc | Houston | Texas |
United States | ARSM Research | Huntersville | North Carolina |
United States | Clinical Research of Lake Norman | Huntersville | North Carolina |
United States | ISA Clinical Research | Jamaica | New York |
United States | Jasper Summit Research LLC | Jasper | Alabama |
United States | New Phase Clinical Research & Development | Knoxville | Tennessee |
United States | Bendel Medical Research Center, LLC | Lafayette | Louisiana |
United States | Clinical Research Advantage Inc | Las Vegas | Nevada |
United States | Gwinnett Biomedical Research | Lawrenceville | Georgia |
United States | Somnos Laboratories, Inc d/b/a Somnos Clinical Research | Lincoln | Nebraska |
United States | Pulmonary Research Institute of Southeast Michigan | Livonia | Michigan |
United States | Southern California Institute For Respiratory Diseases, Inc. | Los Angeles | California |
United States | Delaware Valley Clinical Research, LLC | Marlton | New Jersey |
United States | Clinical Research Institute of Southern Oregon, PC | Medford | Oregon |
United States | Sunstone Medical Research, L.LC | Medford | Oregon |
United States | AppleMed Research, Inc | Miami | Florida |
United States | Clinical Trials of Florida, LLC | Miami | Florida |
United States | Research Institute of South Florida, Inc | Miami | Florida |
United States | LaPorte County Institute For Clinical Research | Michigan City | Indiana |
United States | Clinical Research Institute, Inc. | Minneapolis | Minnesota |
United States | Minnesota Lung Center | Minneapolis | Minnesota |
United States | Clinical Research of Charleston | Mount Pleasant | South Carolina |
United States | New Orleans Center for Clinical Research | New Orleans | Louisiana |
United States | Atlantic Research Center, LLC | Ocean City | New Jersey |
United States | IPS Research Company | Oklahoma City | Oklahoma |
United States | Florida Institute For Clinical Research, LLC | Orlando | Florida |
United States | Ribo Research, LLC dba Peninsula Research, Inc. | Ormond Beach | Florida |
United States | Allergy Associates Research Center | Portland | Oregon |
United States | North Carolina Clinical Research | Raleigh | North Carolina |
United States | Asthma and Allergy Center of Chicago SC | River Forest | Illinois |
United States | Integrated Research Group, Inc | Riverside | California |
United States | Midwest Chest Consultants PC | Saint Charles | Missouri |
United States | CARE Clinical Research | Saint Louis | Missouri |
United States | Midwest Clinical Research LLC | Saint Louis | Missouri |
United States | The Clinical Research Center | Saint Louis | Missouri |
United States | Alamo Clinical Research Associates | San Antonio | Texas |
United States | Institute of Healthcare Assessments Inc. | San Diego | California |
United States | Hope Clinical Research | Seneca | South Carolina |
United States | S. Carolina Pharmaceutical Research | Spartanburg | South Carolina |
United States | Spartanburg Medical Research | Spartanburg | South Carolina |
United States | Pulmonary and Allergy Associates, PA | Summit | New Jersey |
United States | Pulmonary Consultants PLLC | Tacoma | Washington |
United States | Clinical Research of West Florida | Tampa | Florida |
United States | Clinical Research of West Florida, Inc. | Tampa | Florida |
United States | Pulmonary and Critical Care Associates of Baltimore | Towson | Maryland |
United States | Desert Sun Clinical Research LLC | Tucson | Arizona |
United States | CU Pharmaceutical Research | Union | South Carolina |
United States | Buynak Clinical Research, P.C. | Valparaiso | Indiana |
United States | Vero Lung Center | Vero Beach | Florida |
United States | Waterbury Pulmonary Associates, LLC | Waterbury | Connecticut |
United States | PMG Research of Wilmington, LLC | Wilmington | North Carolina |
United States | Southeastern Research Center | Winston-Salem | North Carolina |
United States | Minnesota Lung Center | Woodbury | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Sunovion Respiratory Development Inc. |
United States, Czechia, Hungary, Russian Federation,
Ferguson GT, Goodin T, Tosiello R, Wheeler A, Kerwin E. Long-term safety of glycopyrrolate/eFlow(®) CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Resp — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects With Treatment-emergent Adverse Events (TEAE) | A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date. | Up to Week 48 | |
Primary | Percentage of Subjects With Treatment-emergent Adverse Events | A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date. | Up to Week 48 | |
Primary | Number of Subjects With Treatment-emergent Serious Adverse Events (SAE) | A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date. | Up to Week 48 | |
Primary | Percentage of Subjects With Treatment-emergent Serious Adverse | A treatment emergent serious adverse event (SAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date. | Up to Week 48 | |
Primary | Number of Subjects Who Discontinue the Study Due to TEAE | A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date. | Up to Week 48 | |
Primary | Percentage of Subjects Who Discontinue the Study Due to TEAE | A TEAE is any adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date. | Up to 48 Weeks | |
Secondary | Number of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke | All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs "myocardial infarction", "other ischemic heart disease", "central nervous system hemorrhages and cerebrovascular conditions") were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact. | Up to Week 48 | |
Secondary | Percentage of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke | All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs "myocardial infarction", "other ischemic heart disease", "central nervous system hemorrhages and cerebrovascular conditions") were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact. | Up to 48 Weeks | |
Secondary | Incidence Rate Per 1000 Person Years of Subjects With Major Adverse Cardiac Events (MACE), Including Cardiovascular Death, Ischemia/Infarction, and Stroke | All deaths and any other findings suggestive of a potential MACE (including clinically relevant information and SAEs, and all PTs form the SMQs "myocardial infarction", "other ischemic heart disease", "central nervous system hemorrhages and cerebrovascular conditions") were sent to an adjudication committee for review and categorized as CV death, nonfatal MI, and nonfatal stroke. The MACE score was defined as the total number of subjects with CV deaths, nonfatal MIs, and nonfatal strokes. These events were collected from the first date of study medication until the date of last contact. | up to week 48 | |
Secondary | Mean Change From Baseline Over 48 Weeks in Trough FEV1 for All Subjects | Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the FEV1 values collected at the end of the dosing interval at each clinic visit. The mean change from baseline in trough FEV1 over the 48 week treatment period is calculated by averaging the trough FEV1 changes from baseline across all study visits while subjects are taking randomized treatment. Values affected by other medication use were to be set to missing. |
Up to Week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Terminated |
NCT01388920 -
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
|
Phase 2 |